Retatrutide vs Tesofensine

These sit in different classes. Retatrutide is a GLP-1 / incretin agonist; Tesofensine is a metabolic compound. They get compared because of where they overlap, not because they are interchangeable.

The overlap is appetite control and fat loss. On this site's goal weighting — an editorial priority score, not a measure of effect size — Retatrutide rates 5/5 for appetite control and Tesofensine rates 5/5. Outside that overlap only Retatrutide goes further, carrying weight for metabolic health; Tesofensine's declared goals stop at the overlap.

Tesofensine sits one step firmer: approval from a regulator somewhere, though not a current FDA or EMA label — approved in Mexico at 0.5 mg; the 1 mg arm was clearly worse tolerated. Retatrutide has controlled human trials behind it, without an approval — phase 3 is still running, so there is no long-term safety record. One tier is a real difference but not a decisive one; it should not on its own settle the choice.

Retatrutide is a subcutaneous injection; Tesofensine is taken by mouth. That is the difference most people actually feel: Retatrutide means reconstituting a vial and injecting; Tesofensine does not require either. If needles are the deciding factor, this line settles it before any of the rest matters.

Half-lives are close — 6 days for Retatrutide, 9.2 days for Tesofensine — yet the schedules are not: once a week versus once daily. Similar clearance and different dosing means the difference comes from protocol convention, not from how fast either one leaves you.

One of these has an end date and the other does not: Retatrutide runs no fixed cycle, Tesofensine runs 24 weeks. An open-ended compound is a standing commitment, not a course you finish. Retatrutide also escalates through a titration schedule rather than holding one dose, so its first weeks are not its steady state.

The contraindication lists are not the same: Retatrutide flags MTC or MEN2 history, pancreatitis history, and thyroid disease, which Tesofensine does not; Tesofensine flags under 18, which Retatrutide does not. If any of those describe you they remove a compound from consideration outright, regardless of everything above.

Retatrutide is rated intermediate here and Tesofensine advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.